# Seres Therapeutics, Inc. (MCRB)

> Seres Therapeutics, Inc. (MCRB) trades at $1.44 (+2.13%) as of 7:30:02 PM EST on Nov 18, 2026, -37.66% over the past month. Market cap is $14.37M, with 4.3 days to cover in short interest.

Canonical: https://massive.com/quote/mcrb
Data as of: 2026-11-19T00:30:02.639Z (15-minute delayed)
Source: Massive (https://massive.com/docs/llms.txt)

## Price

**$1.44** +0.03 (+2.13%)
At close · 15-minute delayed
Nasdaq · usd

After hours: **$1.46** +0.02 (+1.39%)
As of 7:30:02 PM EST on Nov 18, 2026 · After hours

## Stock performance

How Seres Therapeutics, Inc. (MCRB) stock has performed from one day to one year, with its 52-week range.

| Period | Return |
| --- | --- |
| 1D | +2.13% |
| 1W | -4.00% |
| 1M | -37.66% |
| YTD | -90.32% |
| 1Y | -94.97% |
| 52-wk range | $1.30 – $29.98 |

From daily closes through Nov 18, 2026.

## Key statistics

Today's trading snapshot for MCRB: day range, open, previous close, volume and market cap.

| Measure | Value |
| --- | --- |
| Day range | $1.41 – $1.58 |
| Open | $1.43 |
| Prev close | $1.41 |
| Volume | 42.97K |
| Market cap | $14.37M |
| Shares out | 10.2M |

## Valuation and profitability ratios

Valuation and profitability ratios for Seres Therapeutics, Inc.: P/E, P/S, P/B, ROE and more.

| Measure | Value |
| --- | --- |
| P/E | — |
| P/S | 6.76 |
| P/B | 0.67 |
| P/FCF | — |
| ROE | -219.8% |
| ROA | -71.3% |
| Debt/Equity | 0.00 |
| Div yield | 0.00% |

As of Nov 17, 2026

## Insider trading

[Seres Therapeutics, Inc. (MCRB) insider trading](https://massive.com/quote/mcrb/insider-trading.md): open-market Form 4 buys and sells by Seres Therapeutics, Inc. insiders over the last 12 months.

## 8-K filings

Material corporate events Seres Therapeutics, Inc. has disclosed to the SEC on Form 8-K.

- Nov 4, 2026 · Investor presentation
  “On November 4, 2026, the Company posted an updated corporate presentation (the "Corporate Presentation") to its website.”
- Oct 26, 2026 · [Cfo departure](https://massive.com/quote/sec-filings/8-k/executive-departures.md)
  “On October 22, 2026, Marella Thorell, Executive Vice President and Chief Financial Officer of Seres Therapeutics, Inc. (the "Company"), resigned from her positions as Executive Vice President and Chief Financial Officer of the Company, effective November 15, 2026 (the "Effective Date").”
- Aug 4, 2026 · Lease agreement
  “On July 31, 2026, Seres Therapeutics, Inc. entered into the Third Amendment to Lease and Termination Agreement with BMR-Sidney Research Campus LLC, the purpose of which is to effect an early termination of one of the Company's leases, reducing the Company's ongoing annual facilities costs and materially eliminating the Company's primary restoration obligations.”
- Jul 8, 2026 · [Clinical trial results](https://massive.com/quote/sec-filings/8-k/clinical-trial-results.md)
  “On July 8, 2026, the Company announced top-line results from an IST evaluating SER-155 in patients with irEC. Following SER-155 dosing, 12 of 15 participants (80%) achieved an immunosuppressive-free clinical response at Day 15, the primary endpoint, defined as at least a 1-grade improvement in diarrhea symptoms without immunosuppressive therapy.”
- Jul 8, 2026 · Annual meeting results
  “On July 8, 2026, at the Annual Meeting, a total of 4,985,176 shares of the Company's common stock were represented in person or by proxy at the meeting, representing approximately 51.75% of the Company's outstanding Common Stock as of the April 13, 2026 record date. Based on the foregoing votes, the director nominees listed in Item 1 were elected and Items 2 through 5 were approved.”

## Dividend history and stock splits

Seres Therapeutics, Inc.'s recent dividend payments and stock splits.

### Dividends

No recent dividends.

### Splits

- 1-for-20 · Apr 22, 2025

## MCRB short interest

How heavily MCRB is shorted: shares short, days to cover and average daily volume.

| Measure | Value |
| --- | --- |
| Days to cover | 4.3 |
| Short interest | 342.24K |
| Avg volume | 79.48K |

As of Oct 30, 2026 · reported to FINRA twice monthly.

## MCRB news

The latest news and headlines about Seres Therapeutics, Inc. (MCRB).

- [Seres Therapeutics to Present Preclinical Data for SER-428, an Investigational Live Biotherapeutic Designed to Reduce Risk of Bloodstream Infections in Critically Ill Patients, at IDWeek 2026](https://www.globenewswire.com/news-release/2026/10/15/3381475/0/en/seres-therapeutics-to-present-preclinical-data-for-ser-428-an-investigational-live-biotherapeutic-designed-to-reduce-risk-of-bloodstream-infections-in-critically-ill-patients-at-id.html) · GlobeNewswire Inc. · Oct 15, 2026 · positive sentiment
- [Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://www.globenewswire.com/news-release/2026/09/08/3358236/0/en/seres-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html) · GlobeNewswire Inc. · Sep 8, 2026 · neutral sentiment
- [Seres Therapeutics Showcases SER-155 Data and Live Biotherapeutic Insights at ESCMID Global 2026](https://www.globenewswire.com/news-release/2026/04/20/3276845/0/en/Seres-Therapeutics-Showcases-SER-155-Data-and-Live-Biotherapeutic-Insights-at-ESCMID-Global-2026.html) · GlobeNewswire Inc. · Apr 20, 2026 · positive sentiment
- [Seres Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates](https://www.globenewswire.com/news-release/2026/03/12/3254451/0/en/Seres-Therapeutics-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Provides-Business-Updates.html) · GlobeNewswire Inc. · Mar 12, 2026 · neutral sentiment
- [$3.25+ Bn Human Microbiome Market Trends and Global Forecasts, 2035, Driven by Advancements in Microbiome Sequencing, Rising Investments in R&D, and Increasing Demand for Personalized Medicine](https://www.globenewswire.com/news-release/2026/02/16/3238647/28124/en/3-25-Bn-Human-Microbiome-Market-Trends-and-Global-Forecasts-2035-Driven-by-Advancements-in-Microbiome-Sequencing-Rising-Investments-in-R-D-and-Increasing-Demand-for-Personalized-Me.html) · GlobeNewswire Inc. · Feb 16, 2026 · positive sentiment

## About Seres Therapeutics, Inc.

Seres Therapeutics Inc is a clinical-stage biotechnology company focused on the development of live biotherapeutic candidates. Its pipeline includes candidates such as SER-155 and SER-603, aimed at preventing and treating bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases. The company operates as a single reportable segment, mainly developing microbiome-based therapies targeting bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases.

| Measure | Value |
| --- | --- |
| Exchange | Nasdaq |
| Market | stocks |
| Type | CS |
| Currency | USD |
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 66 |
| Listed | Jun 26, 2015 |

[Company website](https://www.serestherapeutics.com)

## FAQ

### What is the Seres Therapeutics, Inc. (MCRB) stock price today?

Seres Therapeutics, Inc. (MCRB) is trading at $1.44 (+2.13% on the day) as of 7:30:02 PM EST on Nov 18, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.

### What is Seres Therapeutics, Inc.?

Seres Therapeutics Inc is a clinical-stage biotechnology company focused on the development of live biotherapeutic candidates. Its pipeline includes candidates such as SER-155 and SER-603, aimed at preventing and treating bacterial infections, antimicrobial resistance, and…

### What is the short interest in MCRB?

As of Oct 30, 2026, MCRB has 342.24K shares short and 4.3 days to cover.

### What exchange is MCRB listed on?

Seres Therapeutics, Inc. (MCRB) trades on Nasdaq in USD, in the PHARMACEUTICAL PREPARATIONS industry.

## Live data

Prices here are 15-minute delayed. For real-time MCRB quotes and the full history behind this page, use the Massive API or MCP server:

- `GET https://api.massive.com/v3/snapshot?ticker.any_of=MCRB`

Requests need a Massive API key. API reference for agents: https://massive.com/docs/llms.txt. Connect an AI agent through the Massive MCP server: https://massive.com/docs/ai-tools.

## Related

- [Seres Therapeutics, Inc. (MCRB) insider trading](https://massive.com/quote/mcrb/insider-trading.md)
- [SEC 8-K events](https://massive.com/quote/sec-filings/8-k.md)
- [Markets overview](https://massive.com/quote/index.md)

Nothing here is investment advice. Data and content are provided for informational purposes under the Massive Terms of Service: https://massive.com/terms
